Results 11 to 20 of about 3,600,128 (335)

Considerations on the Obstacles That Lead to Slow Recruitment in a Pain Management Clinical Trial: Experiences from the Belgian PELICAN (PrEgabalin Lidocaine Capsaicin Neuropathic Pain) Pragmatic Study

open access: yesPain Research and Management, 2023
Background. A qualitative evaluation study of the prematurely terminated PrEgabalin Lidocaine Capsaicin Neuropathic Pain (PELICAN) study was performed.
Guy H. Hans   +8 more
doaj   +1 more source

Development and Validation of a Prediction Model for Venous Thrombus Embolism (VTE) in Patients With Colorectal Cancer

open access: yesTechnology in Cancer Research & Treatment, 2023
Cancer patients are at high risk of developing venous thromboembolism (VTE). The risk of VTE could be mitigated with the administration of prophylactic anticoagulants.
Wei-Juan Tan MS   +6 more
doaj   +1 more source

Effect of a high‐fat and high‐calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects

open access: yesPharmacology Research & Perspectives, 2023
HSK16149 is a novel, potent gamma‐aminobutyric acid (GABA) analog for the treatment of neuropathic pain. The purpose of this study was to assess the effect of a high‐fat and high‐calorie meal on the pharmacokinetics of HSK16149 in healthy Chinese ...
Qingqing Wu   +9 more
doaj   +1 more source

Differential impact of osteoporosis, sarcopenia and obesity on physical performance in aging men

open access: yesEndocrine Connections, 2021
Purpose: Aging and concurrent constitutional changes as sarcopenia, osteoporosis and obesity are associated with progressive functional decline. Coincidence and mutual interference of this risk factors require further evaluation.
Franca Genest   +4 more
doaj   +1 more source

Co-expression and prognosis analyses of GLUT1–4 and RB1 in breast cancer

open access: yesBMC Cancer, 2021
Background Current treatment methods for patients with triple-negative breast cancer (TNBC) are very limited, and the prognosis of TNBC is relatively poor.
Xiaodan Zhang   +6 more
doaj   +1 more source

Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
PB‐201 is the second glucokinase activator in the world to enter the phase III clinical trials for the treatment of type 2 diabetes mellitus (T2DM).
Miao Zhang   +6 more
doaj   +1 more source

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]

open access: yes, 2020
Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.)   +13 more
core   +1 more source

Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]

open access: yes, 2019
Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita   +2 more
core   +3 more sources

The prevention and treatment of COVID-19 in patients treated with hemodialysis

open access: yesEuropean Journal of Medical Research, 2023
Patients treated with hemodialysis are often immunocompromised due to concomitant disease. As a result, this population is at high risk of infection and mortality from COVID-19.
Binyu Zeng   +4 more
doaj   +1 more source

Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned [PDF]

open access: yes, 2017
Background Clinical trial success depends on appropriate management, but practical guidance to trial organisation and planning is lacking. The Incident Command System (ICS) is the ‘gold standard’ management system developed for managing diverse ...
Michael, Mary J.   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy